drugset
drugset / Trial / NCT06087770

Clinical Study of SM3321 With Solid Tumors

NCT06087770 ↗

Phase 1 Unknown 48 enrolled Beijing StarMab Biomed Technology Ltd
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the Safety and Tolerability of SM3321 in patients with locally advanced or metastatic solid tumors

Timeline

Start
2023-12-07
Primary completion
2025-08-19
Completion
2025-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject SM3321 Unknown 0.3 mg/kg Intravenous
Subject SM3321 Unknown 1 mg/kg Intravenous
Subject SM3321 Unknown 3 mg/kg Intravenous
Subject SM3321 Unknown 10 mg/kg Intravenous
Subject SM3321 Unknown 20 mg/kg Intravenous
Subject SM3321 Unknown 30 mg/kg Intravenous
Subject SM3321 Unknown 40 mg/kg Intravenous
Subject SM3321 Unknown 50 mg/kg Intravenous

Indications

No indication recorded.